The HPRA advises healthcare professionals not to retain printed versions of Summary of Product Characteristics (SPC) documents. As these documents are subject to frequent content updates, including changes to safety and dose related information, we recommend that you visit our website as necessary to access the most up-to-date versions. If you have any queries about specific SPCs on our website then please e-mail info@hpra.ie


Cefuroxime 750 mg powder for solution for injection/infusion



Fresenius Kabi Deutschland GmbHPA2059/006/001

Main Information

Trade NameCefuroxime 750 mg powder for solution for injection/infusion
Active SubstancesCefuroxime Sodium
Dosage FormPowder for solution for injection/infusion
Licence HolderFresenius Kabi Deutschland GmbH
Licence NumberPA2059/006/001

Group Information

ATC CodeJ01DC Second-generation cephalosporins
J01DC02 cefuroxime

Status

License statusAuthorised
Licence Issued21/08/2009
Legal statusProduct subject to prescription which may not be renewed (A)
Supply StatusSupply through pharmacies only
Advertising StatusAdvertising to healthcare professionals only
Conditions of Licence
Marketing StatusMarketed

Documents

Summary of Product CharacteristicsPDF Version
Package LeafletPDF Version
Public Assessment ReportNo document available
« Back